SELLAS Life Sciences
31 hedge funds and large institutions have $13.3M invested in SELLAS Life Sciences in 2021 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 4 closing their positions.
250% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 4
200% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 3
147% more capital invested
Capital invested by funds: $5.37M → $13.3M (+$7.88M)
48% more funds holding
Funds holding: 21 → 31 (+10)
16% more call options, than puts
Call options by funds: $2.41M | Put options by funds: $2.07M
2.44% more ownership
Funds ownership: 7.85% → 10.29% (+2.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.37M |
| 2 |
BlackRock
New York
|
+$1.24M |
| 3 |
Nomura Holdings
Tokyo,
Japan
|
+$1.08M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$495K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$424K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$877K |
| 2 |
Jane Street
New York
|
-$112K |
| 3 |
Squarepoint
New York
|
-$59K |
| 4 |
VF
Virtu Financial
New York
|
-$39.7K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$19K |
SLS Hedge Fund Activity: Q1 2021 in Review
31 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in SELLAS Life Sciences (SLS) for Q1 2021, worth a combined $13.3M — up 147% from $5.37M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new SLS positions and 4 closed out — a net gain of 10 holders — while 9 added to existing stakes and 3 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $1.37M. The largest seller was Vanguard Group, cutting an estimated $877K.
- 31 institutional investors held SELLAS Life Sciences (SLS) as of Q1 2021, up from 21 in Q4 2020.
- Funds reported $13.3M of SELLAS Life Sciences stock for Q1 2021, up 147% quarter-over-quarter.
- 14 funds opened new SELLAS Life Sciences positions in Q1 2021 and 4 closed out, a net change of +10 holders.
- The largest SELLAS Life Sciences buyer in Q1 2021 was Susquehanna International Group, an estimated $1.37M added.
- The largest SELLAS Life Sciences seller in Q1 2021 was Vanguard Group, an estimated $877K sold.
Based on aggregated 13F filings for Q1 2021.